April 05, 2019 | Featured
5th April 2019, London, UK and Tokyo, Japan: Intract Pharma Ltd (“Intract”) and Neopharma Japan Co. Ltd (“NPJ”), have announced entry into a collaboration to develop a novel therapeutic product for treatment of gastrointestinal diseases using Intract’s proprietary drug delivery technologies. Intract is a leader in oral drug delivery, building on over 20 years of research and an in-depth understanding of gastrointestinal physiology for optimal drug product development. NPJ, a subsidiary of Neopharma UAE, is a global center of excellence for research and development of innovative medicines and healthcare products.
Under the terms of the collaboration, details of which have not been made public, Intract will provide NPJ access to its proprietary drug formulation platforms for creation of improved medical products. The programme will be advanced rapidly to the clinic through use of Intract’s will specialist pre-clinical gastrointestinal models.
Commenting on the collaboration, Bill Lindsay, Intract’s CEO said “Intract is delighted to enter this very exciting collaboration with NPJ. Intract is driven to see its technologies and expertise result in benefit to patients through such innovative projects.”
“We are very excited to bring our promising compound to the patients suffering from gastrointestinal diseases through the collaboration with Intract”, said Satofumi Kawata, NPJ’s Representative Director.
Details of the drug compound and financial terms were not disclosed.
About Intract: Intract Pharma Ltd offers access to unique know-how and technologies for optimized oral delivery of drugs. Intract’s GI models allow development of detailed knowledge of drug solubility, stability and uptake, to enable optimal bespoke drug formulations with improved bioavailability and efficacy. For more information, visit www.intractpharma.com
About Neopharma: Neopharma LLC UAE is one of the largest pharmaceutical companies in the MENA region with presence in over 50 countries. Neopharma is an integrated pharmaceutical company currently having manufacturing operations in Japan, India, Brazil and UAE, primarily focusing on novel therapeutics and debilitating diseases at affordable prices. For more information, visit www.neopharma.com
Copyright © 2018 Intract Pharma
Website Design by Creative Brand Design